News Archives » pediatric aids drugs
Important Advances in Pediatric AIDS Drug Development December 3rd, 2014
World AIDS Day saw two important announcements regarding development of much-needed pediatric AIDS drugs. This is an issue on which the Oblates and other faith-based investors in the Interfaith Center on Corporate Responsibility (ICCR) have pressed pharmaceutical companies on for years. Since most pediatric AIDS patients are in poor, developing countries, the usual market incentive for drug development does not exist. And, the development of pediatric AIDS drugs, particularly for infants, is challenging. ICCR members have actively encouraged the major pharmaceutical companies to participate in the Medicines Patent Pool, a mechanism established under the auspices of the UN to ‘pool’ patents for drugs to make existing formulations more readily available for generic production and for innovative fixed dose combinations to be developed.
On Monday, World AIDS Day, Abbvie announced a licensing agreement for lopinavir (LPV) and ritonavir (r), top World Health Organization-recommended medicines for children. The license will enable other companies and organizations to re-formulate and manufacture specially designed LPV/r and r pediatric treatments for distribution in low- and middle-income countries where 99% of children with HIV in the developing world live. [Abbvie is a spinoff of Abbott Laboratories that contains the research-based pharmaceutical business.]
On the same day, the HIV Medicines Research Industry Forum announced that the forum is joining PEPFAR, the Global Fund, and the Pediatric HIV Treatment Initiative (PHTI) in the newly established “Global Pediatric Antiretroviral (ARV) Commitment-to-Action” to accelerate innovation and save children’s lives. The initiative is designed to accelerate the development of new, high-priority pediatric ARV co-formulations for first- and second-line treatment by 2017.
Click here to read more »